Edward Mascioli

Peptimmune was founded in 2002 with technology from the laboratories of Dr. Jack Strominger, Higgins Professor of Biochemistry at Harvard University; and Dr. Hidde Ploegh, from the Whitehead Institute for Biomedical Research. Peptimmune has therapeutics in clinical development for the treatment of multiple sclerosis. Peptimmune's flagship program in multiple sclerosis features PI-2301, which has the opportunity to replace Copaxone® (Teva Pharmaceuticals), the world's leading first-line therapy for the treatment of MS. Peptimmune has broad expertise in MHC Class II molecules and their role in antigen presentation and modulation of immune responses. The Company exploits its proprietary DEEP Technology (Directed Expansion of Epitope Permutation) to design peptides and peptide mixtures for development as therapeutics, diagnostic kits, and as reagents for antibody generation. The Company is building a unique suite of expertise in the manufacture and control of peptide copolymer-based drug products.

Part of Community Health Systems, Inc., Deaconess Hospital is a 313-bed hospital based in Oklahoma City, OK. The hospital provides medical services to patients in the area.

Affinium Pharmaceuticals Ltd. is a holding company, which engages in the provision of clinical development of antibacterial. It specializes in hte development of antibiotics that targets the bacterial fatty acid synthesis pathway. It focuses on small molecule antibacterials targeting FabI, an essential enzyme in the bacterial fatty acid cycle. The company was founded in 2000 and is headquartered in Austin, TX.

SV Health Investors LLP (SV Health Investors) is a venture capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London.

Sancilio Pharmaceuticals Co. engaged in the development and manufacture of pharmaceutical products. Its product platform, advanced lipid technologies, focuses on the treatment of diseases and disorders related to lipids such as sickle cell, short bowel, severe hypertriglyceridemia and non-alcoholic fatty liver. The company was founded by Frederick Sancilio in October 2004 and was headquartered in Riviera Beach, FL.

Sancilio & Co., Inc. operates as specialty pharmaceutical company. It develops and markets based products including those based on the proprietary Advanced Lipid Technologies platform. The company was founded by Frederick D. Sancilio in 2005 and is headquartered in Riviera Beach, FL.

Karos Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. The firm focuses on bone related, pulmonary arterial hypertension and other orphan diseases. The company was founded in 2009 and is headquartered in New Haven, CT.

Cardurion Pharmaceuticals LLC is a cardiovascular biotechnology company, which engages in the development of therapeutics for the treatment of heart failure and cardiovascular diseases. The company was founded by Michael E. Mendelsohn in 2017 and is headquartered in Boston, MA.

Matrivax Research & Development Corp. is developing human vaccines for the prevention and treatment of life-threatening bacterial diseases. Its pipeline includes two vaccine candidates implementing proprietary streptococcus pneumoniae and clostridium difficile protective antigens. The company was founded in October 2007 and is headquartered in Boston, MA.